Assertio Therapeutics (ASRT) Misses Q2 EPS by 32c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. SKYD
6. BBIO
7. SPY
8. RCKT
9. NVDA
10. CRBU

Go back to Assertio Therapeutics (ASRT) Misses Q2 EPS by 32c, Revenues Miss

Assertio Reports Second Quarter 2020 Financial Results

August 7, 2020 6:03 AM EDT

--Completed all merger and integration activities in Q2--
--Repaid $10 million of Senior Secured Notes ahead of schedule--
--Zyla products partially contributed to Q2 net product sales of $20.2 million--
--Combined second quarter 2020 net product sales of $27.7 million, on a pro forma basis, increased modestly over pro forma first quarter 2020 despite COVID-19 and merger integration--

LAKE FOREST, Ill., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today reported financial results for the second quarter ended June 30, 2020. During the... More